NEW YORK CITY, NY / ACCESS Newswire / March 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

The UK MHRA has validated Bavarian Nordics’ marketing authorisation application for its single-dose chikungunya vaccine.

The global attenuated vaccines market is set for remarkable expansion, with sales projected to surge from USD 5,068.2 million in 2024 to an estimated USD 9,693.9 million by 2034. This growth ...

From a historic vaccine approval to a $50bn investment reshaping US drug manufacturing, February brought major pharma news to ...

Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ...

HC Wainwright reaffirmed their buy rating on shares of Valneva (NASDAQ:VALN – Free Report) in a report published on Friday morning,Benzinga reports. HC Wainwright currently has a $17.00 price ...

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 – ...

CDC investigating 5 hospitalizations in people 65+ for cardiac/neurologic events after receiving Valneva's Ixchiq chikungunya ...

The IXCHIQ vaccine, administered as a single-dose shot into the muscle, contains a live, weakened version of the chikungunya virus. The vaccine, manufactured by the biotechnology company Valneva, was ...

The IXCHIQ vaccine, administered as a single-dose shot into the muscle, contains a live, weakened version of the chikungunya virus. The vaccine, manufactured by the biotechnology company Valneva ...